Tatva Chintan Pharma Chem Ltd's Q4FY25 Quarter Results
- 03 May 2025
Result Summary
- Tatva Chintan Pharma Chem Ltd reported a 19.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 18.0%.
- Its expenses for the quarter were up by 3.4% QoQ and down 21.8% YoY.
- The net profit increased 6764.3% QoQ and decreased 43.3% YoY.
- The earnings per share (EPS) of Tatva Chintan Pharma Chem Ltd stood at 4.1 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 102.79 | 85.94 | 125.36 | 19.6% | -18.0% |
Total Expenses | 89.10 | 86.18 | 113.97 | 3.4% | -21.8% |
Profit Before Tax | 13.69 | -0.24 | 7.80 | -5804.2% | 75.5% |
Tax | 4.08 | -0.37 | -9.15 | -1202.7% | -144.6% |
Profit After Tax | 9.61 | 0.14 | 16.95 | 6764.3% | -43.3% |
Earnings Per Share | 4.10 | 0.10 | 7.70 | 4000.0% | -46.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Tatva Chintan Pharma Chem Ltd is a company operating in the specialty chemical industry. The company is known for producing a variety of specialty chemicals, which include phase transfer catalysts, structure-directing agents, and electrolyte salts for supercapacitor batteries. These products are used in several applications across different industries, including pharmaceuticals, agrochemicals, dyes, and pigments. The company has been actively involved in expanding its product portfolio and enhancing its production capabilities to cater to the growing demand for specialty chemicals globally. Recent developments include investments in research and development to innovate and improve its product offerings, aligning with the industry's evolving needs.
Revenue
In the fourth quarter of the fiscal year 2025 (Q4FY25), Tatva Chintan Pharma Chem Ltd reported a total income of ₹102.79 crores. This represents a 19.6% increase from the previous quarter (Q3FY25), where the income was ₹85.94 crores. However, comparing year-over-year, there was an 18.0% decline from Q4FY24, when the total income was ₹125.36 crores. This demonstrates a fluctuation in revenue generation, with a notable increase in the most recent quarter against the preceding one, yet a decline when looking at the same period in the previous year. Such variations in revenue can be attributed to multiple factors including market conditions, demand fluctuations in the specialty chemicals sector, and operational changes.
Profitability
The profitability metrics for Tatva Chintan Pharma Chem Ltd reflect significant changes over the periods in question. The company reported a Profit Before Tax (PBT) of ₹13.69 crores in Q4FY25, a substantial improvement from a loss of ₹0.24 crores in Q3FY25, marking a quarter-over-quarter increase of 5804.2%. Year-over-year, the PBT increased by 75.5% from ₹7.80 crores in Q4FY24. The Profit After Tax (PAT) for Q4FY25 was ₹9.61 crores, up from ₹0.14 crores in Q3FY25, and down from ₹16.95 crores in Q4FY24, indicating a 6764.3% QoQ increase and a 43.3% YoY decrease. Earnings Per Share (EPS) followed a similar trend, with a QoQ increase to ₹4.10 from ₹0.10 but a YoY decrease from ₹7.70. These figures highlight a recovery in profitability compared to the previous quarter but a decline when compared to the previous year's fourth quarter.
Operating Metrics
The company's expenses also exhibited notable trends. Total expenses for Q4FY25 were ₹89.10 crores, which represents a 3.4% increase from Q3FY25, where expenses were ₹86.18 crores. Compared to Q4FY24, expenses decreased by 21.8% from ₹113.97 crores. The tax figures show a significant change, with a tax expense of ₹4.08 crores in Q4FY25, contrasting with a tax credit in Q3FY25 of -₹0.37 crores and a significant tax credit of -₹9.15 crores in Q4FY24. These variations in operating metrics, particularly the expenses and tax, reflect shifts in the company’s operational dynamics and financial strategies. The changes in these metrics provide insight into the company's cost management and tax planning over the analyzed periods.
